Comparing Longeveron (NASDAQ:LGVN) and Senti Biosciences (NASDAQ:SNTI)
by Sarita Garza · The Markets DailySenti Biosciences (NASDAQ:SNTI – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Earnings and Valuation
This table compares Senti Biosciences and Longeveron”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $2.56 million | 11.71 | -$52.79 million | ($3.33) | -0.34 |
| Longeveron | $2.39 million | 4.77 | -$15.97 million | ($1.06) | -0.50 |
Longeveron has lower revenue, but higher earnings than Senti Biosciences. Longeveron is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Senti Biosciences has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Senti Biosciences and Longeveron, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 4 | 1 | 2.83 |
| Longeveron | 1 | 0 | 2 | 0 | 2.33 |
Senti Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 689.47%. Longeveron has a consensus target price of $6.50, suggesting a potential upside of 1,114.95%. Given Longeveron’s higher possible upside, analysts clearly believe Longeveron is more favorable than Senti Biosciences.
Profitability
This table compares Senti Biosciences and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -197.68% | -63.05% |
| Longeveron | -1,485.25% | -138.44% | -108.46% |
Institutional & Insider Ownership
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 11.2% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Senti Biosciences beats Longeveron on 10 of the 15 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.